MedPath

Comparison the effects of Donepezil, Galantamine,Rivastigmine and Memantine on vascular dementia.

Phase 2
Recruiting
Conditions
Vascular Dementia.
occlusion and stenosis of cerebral and precerebral arteries (including truncus brachiocephalicus), resulting in cerebral infarction
Registration Number
IRCT20181210041912N1
Lead Sponsor
Kerman University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
44
Inclusion Criteria

Patients with vascular dementia in Kerman city

Exclusion Criteria

Having any underlying condition other than diabetes, hypertension, hyperlipidemia, and ischemic heart disease, including history of depression and memory and speech impairment.
Use of any medication, such as sedative medicines and substance abuse, except medicines for controlling diabetes, hypertension, hyperlipidemia, and ischemic heart disease.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Transcranial Doppler Sonography. Timepoint: Performing transcranial doppler sonography at the beginning of the study and three months after taking any of the donepezill, memantine, galanthamine or rivastigmine drugs. Method of measurement: Doppler Sonography machine.
Secondary Outcome Measures
NameTimeMethod
Mini Mental State Examination. Timepoint: Measurement of the MMSE at the beginning of the study and three months after the onset of consumption, which of the drugs donepezil, memantine, galantamine or rivastigmine. Method of measurement: By number from zero to thirty.
© Copyright 2025. All Rights Reserved by MedPath